Gilead unveils $6 million HIV and viral hepatitis initiative for Australian and Canadian indigenous communities
Gilead Sciences has said it will make its largest commitment to health equity for indigenous communities across Australia and Canada.
Archives for July 25, 2023
Gilead scraps phase 3 trial of blood cancer treatment
Gilead Sciences has decided to end a phase 3 trial of magrolimab for higher-risk myelodysplastic syndromes (MDS) after an analysis suggested it would be futile to continue.
ImmunoGen to develop next-generation ADCs with ImmunoBiochem
ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm...
Teva Pharmaceuticals and Alvotech expand strategic biosimilars partnership
Teva Pharmaceuticals, a provider of generic and innovative medicines, and Alvotech, a biotech company specializing in the development and manufacture of biosimilar medicines, have expanded their existing partnership agreement.